Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease

NCT ID: NCT04966221

Last Updated: 2022-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to use novel proton-based MRI techniques to assess lung function and structure in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD) and alpha-1-anti-trypsin deficiency (A1ATD). These novel MRI measures will be compared to matched contemporary clinical diagnostic tools, namely pulmonary function tests (PFTs) and computed tomography (CT) scans. MRI has the advantages of avoiding ionising radiation exposure (unlike CT scans) and can also provide regional measures of lung function (unlike PFTs which provide global measures of function). In addition, these MRI techniques do not require the use of any inhaled or injected contrast agents.

Some patients enrolled in this study will be undergoing a lung volume reduction (LVR) procedure as part of their normal clinical care. LVR is an intervention for patients with severe lung disease and hyperinflation. It is a palliative therapy that helps to reduce lung hyperinflation through insertion of small valves in the airway or surgical removal of parts of the lung. This can lead to improvements in symptoms such as breathlessness and improve exercise tolerance due to better functioning of the lung. In this study, we will explore how lung MRI measures can be used to assess patients before and after an LVR intervention.

This study will take place at the University of Nottingham in collaboration with Nottingham University Hospitals NHS Trust. The study will last for 3 years and participants will be asked to attend a screening visit (lasting up to 1 hour) and either one or two study visits (each lasting up to 3 hours).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single centre pilot study. The research team aims to recruit adult healthy volunteers and adult patient volunteers with COPD and A1ATD. We have used similar proton-based MRI techniques in healthy volunteers and people with other lung diseases and the MRI scans have been well tolerated.

All participants will be adults (both male and female) who can give informed consent and are able to undertake the study procedures. Potential participants who cannot have an MRI scan for safety reasons (e.g. have a pacemaker) will not be recruited. During study visits, all research activities will be observed by a member of the research team.

During the screening visit (following consent), the following information and measures will be taken:

Relevant past medical history, COPD assessment tool (questionnaire), height, weight, blood pressure and pulse oximetry.

During study visits, a combination of structural and functional lung MRI scans will be performed with the participant lying in the scanner. Participants will be asked to breathe normally during scans and may also be asked to perform breathing manoeuvres such as holding their breath temporarily.

The participants will be assigned unique codes, and their data will be anonymised. Participants' medical reports will only be accessed for study purposes and will be treated as confidential.

The investigators will aim to use the data to plan future studies, and the data from this study may contribute to publications and presentations. Participants will not be identified in any publications arising from the research. The data obtained will be published without any identifying information.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease Alpha 1-Antitrypsin Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult healthy volunteers

Adult healthy volunteers, age matched to patient volunteers. Will undergo a combination of functional and structural lung MRI scans.

Lung MRI scan

Intervention Type DIAGNOSTIC_TEST

Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Adults with Chronic Obstructive Pulmonary Disease

Will undergo a combination of functional and structural lung MRI scans. Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care. These participants will be given the option to attend two study visits - one before and one after LVR.

Lung MRI scan

Intervention Type DIAGNOSTIC_TEST

Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Adults with alpha-1-antitrypsin deficiency

Will undergo a combination of functional and structural lung MRI scans.

Lung MRI scan

Intervention Type DIAGNOSTIC_TEST

Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung MRI scan

Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 18 years and over
* Capacity to give informed consent
* Normal blood pressure (systolic BP \> 90 mmHg and diastolic BP \>50 mmHg)
* Resting heart rate \> 50bpm
* For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
* Subject able to hold breath for 10 seconds
* Subject able to understand the requirements of the study and to cooperate with the study procedures
* Subject has normal lung function by spirometry criteria
* Smoking history of \> 10 pack years of tobacco smoking


* Male or female aged 18 years and over
* Capacity to give informed consent
* Normal blood pressure (systolic BP \> 90 mmHg and diastolic BP \>50 mmHg)
* Resting heart rate \> 50bpm
* For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
* Subject able to hold breath for 10 seconds
* Subject able to understand the requirements of the study and to cooperate with the study procedures
* Diagnosis of COPD made by respiratory physician and confirmed by spirometry criteria (FEV1/FVC ratio \< 0.7) and \> 10 pack years of tobacco smoking.


* Male or female aged 18 years and over
* Capacity to give informed consent
* Normal blood pressure (systolic BP \> 90 mmHg and diastolic BP \>50 mmHg)
* Resting heart rate \> 50bpm
* For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
* Subject able to hold breath for 10 seconds
* Subject able to understand the requirements of the study and to cooperate with the study procedures
* Diagnosis of A1ATD (PiZZ or PiZ-) and either evidence of emphysema on a previous clinical CT scan or evidence of airways obstruction

Exclusion Criteria

* Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
* Subject deemed unlikely to comply with instructions during imaging
* Subject not deemed fit enough to tolerate procedure
* Subject deemed unsuitable by clinical investigator for other reasons
* Abnormal spirometry


* Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
* Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this instance, the subject will be invited to be rescreened \> 4 weeks later.
* Subject deemed unlikely to comply with instructions during imaging
* Subject not deemed fit enough to tolerate procedure
* Subject deemed unsuitable by clinical investigator for other reasons


* Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
* Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this case, the subject will be rescreened \>4 weeks later
* Subject deemed unlikely to comply with instructions during imaging
* Subject not deemed fit enough to tolerate procedure
* Subject deemed unsuitable by clinical investigator for other reasons
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nottingham University Hospitals NHS Trust

OTHER

Sponsor Role collaborator

University of Nottingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathan Brooke

Clinical Research Fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan Philip Brooke

Role: PRINCIPAL_INVESTIGATOR

The University of Nottingham

Zachary Peggs

Role: PRINCIPAL_INVESTIGATOR

The University of Nottingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sir Peter Mansfield Imaging Centre, University of Nottingham

Nottingham, Nottinghamshire, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan Philip Brooke

Role: CONTACT

01158231154

Zachary Peggs

Role: CONTACT

01158231154

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Richard Bowtell, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21048

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Disease-syndrome Characteristics of IPF
NCT07178392 NOT_YET_RECRUITING
Functional Applications of Hyperpolarized 129Xe MRI
NCT01697332 TERMINATED PHASE1/PHASE2